Shares of Jiangsu Hengrui Pharmaceuticals soared Friday morning, as more companies seek to tap Hong Kong’s capital markets.

Theodore Shou, CEO of Yiyi Capital, discusses the recent strong performance of the IPO market in Hong Kong and says that the valuation premium between mainland China and Hong Kong stocks would narrow ...

Singapore biotech firm Mirxes began trading in Hong Kong on May 23 at a valuation exceeding US$1 billion. Read more at ...

Lihan Zhou, CEO and Co-Founder of Mirxes, a Singapore-based bio-test company, discusses the company's Hong Kong IPO and ...

The Chinese drugmaker raised HK$9.74 billion, equivalent to US$1.25 billion, in net proceeds, making it one of Hong Kong's largest IPOs so far this year. The stock was priced at HK$44.05 per share, ...

In related news, Singapore-based pharmaceutical company Mirxes, which specializes in cancer treatment, also had a strong debut in Hong Kong on the same day. The company’s shares rose by 28% in morning ...

In response to Fitch maintaining Hong Kong's AA- credit rating and stable outlook, the Hong Kong Special Administrative ...

Health-care companies fell, but not by as much as the broad market, as the defensive bias on the stock market bolstered two new issues in the sector. Shares of Chinese drugmaker Jiangsu Hengrui ...

Dow Jones Top Company Headlines at 11 AM ET: Booz Allen to Cut 2,500 Jobs as Business Grapples With Trump Spending Crackdown | Trump ... Booz Allen to Cut 2,500 Jobs as Business Grapples With Trump ...

Singapore-based cancer diagnostics firm MiRXES has listed on the Hong Kong Stock Exchange, with shares jumping 24.5% above the HKD 23.3 offer price on debut. The stock was trading at HKD 30 as of 3:00 ...

For years, Dominari Holdings’ shifting priorities and tribulations remained largely out of the spotlight. That changed when ...

Hong Kong stocks generally maintained their strong momentum, with the weekly performances of the three major indices varying. By the close of trading, the Hang Seng Index (HSI) had risen by 1.10% week ...